Relapsed/Refractory B-cell Malignancies Clinical Trials

16 clinical trials for Relapsed/Refractory B-cell Malignancies across international registries, including 6 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• IASO208 Injection in the Treatment of Relapsed/Refractory B-cell Malignancies — RECRUITING · PHASE1
• The CD19/CD20 Dual-Target in Vivo CAR-T Lentiviral Product in the Treatment of Relapsed/Refractory B-cell Malignancies — RECRUITING · PHASE1
• Clinical Study Evaluating the Safety and Efficacy of BAFFR CAR-T Therapy for Relapsed/Refractory B-cell Malignancies — RECRUITING · NA
• Safety and Efficacy of ZZSW-01 in Relapsed/Refractory B-cell Malignancies — RECRUITING · PHASE1
• UBX-303061 in Subjects With Relapsed/Refractory B-Cell Malignancies — RECRUITING · PHASE1
• A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies — RECRUITING · PHASE1
• CD19/CD20 Dual-Target in Vivo CAR-T Lentiviral Product in the Treatment of Relapsed/Refractory B-cell Malignancies — NOT_YET_RECRUITING · PHASE1
• A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies — TERMINATED · PHASE1
• A Study of the LVIVO-TaVec122 Product in Subjects With Relapsed/Refractory B-cell Malignancies — NOT_YET_RECRUITING · PHASE1
• Phase I Clinical Study to Evaluate SYS6055 Injection in Participants With Relapsed/Refractory B-Cell Malignancies — NOT_YET_RECRUITING · PHASE1
• A Study to Learn More About an Investigational Medicine called HDP-102 in Patients with Relapsed/Refractory B-cell Blood Cancers. — OTHER · PHASE1
• Phase I/II, FIH, Dose Escalation Trial of TL-895 and Expansion of TL-895 Monotherapy and Combination Therapy With Navtemadlin in Tx-Naïve and R/R CLL/SLL Subjects — OTHER · PHASE1
• A Study of HSK29116 in Adults With Relapsed/Refractory B-cell Malignancies — OTHER · PHASE1
• Study to Assess the Long-term Safety and Efficacy of Tirabrutinib in Adults With Relapsed/Refractory B-cell Malignancies — COMPLETED · PHASE1
• This is a Phase 1 Study of MH048 in Patients With Selected Relapsed/Refractory B-cell Malignancies — OTHER · PHASE1
• CD19 CAR T Cells in Children and Adults With Relapsed or Refractory CD19 Positive B Cell Malignancies — OTHER · PHASE1

Refine this search